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RESEARCH ARTICLE Open Access
Membrane associated collagen XIII
promotes cancer metastasis and enhances
anoikis resistance
Hui Zhang1,2, Tricia Fredericks4, Gaofeng Xiong2, Yifei Qi2, Piotr G. Rychahou5, Jia-Da Li6, Taina Pihlajaniemi7,
Wei Xu1* and Ren Xu2,3*
Abstract
Background: Increased collagen expression and deposition are associated with cancer progression and poor
prognosis in breast cancer patients. However, function and regulation of membrane-associated collagen in breast
cancer have not been determined. Collagen XIII is a type II transmembrane protein within the collagen superfamily.
Experiments in tissue culture and knockout mouse models show that collagen XIII is involved in cell adhesion and
differentiation of certain cell types. In the present study, we determined roles of collagen XIII in breast cancer
progression and metastasis.
Methods: We analyzed the association of collagen XIII expression with breast cancer development and metastasis
using published gene expression profiles generated from human breast cancer tissues. Utilizing gain- and loss- of
function approaches and 3D culture assays, we investigated roles of collagen XIII in regulating invasive tumor
growth. Using the tumorsphere/mammosphere formation assay and the detachment cell culture assay, we
determined whether collagen XIII enhances cancer cell stemness and induces anoikis resistance. We also inhibited
collagen XIII signaling with β1 integrin function-blocking antibody. Finally, using the lung colonization assay and
the orthotopic mammary tumor model, we investigated roles of collagen XIII in regulating breast cancer
colonization and metastasis. Cox proportional hazard (log-rank) test, two-sided Student’s t-test (two groups) and
one-way ANOVA (three or more groups) analyses were used in this study.
Results: Collagen XIII expression is significantly higher in human breast cancer tissue compared with normal
mammary gland. Increased collagen XIII mRNA levels in breast cancer tissue correlated with short distant recurrence
free survival. We showed that collagen XIII expression promoted invasive tumor growth in 3D culture, enhanced
cancer cell stemness, and induced anoikis resistance. Collagen XIII expression induced β1 integrin activation.
Blocking β1 integrin activation significantly reduced collagen XIII-induced invasion and mammosphere formation.
Importantly, silencing collagen XIII in MDA-MB-231 cells reduced lung colonization and metastasis.
Conclusions: Our results demonstrate a novel function of collagen XIII in promoting cancer metastasis, cell
invasion, and anoikis resistance.
Keywords: Extracellular matrix, Membrane-associated collagen, Stemness, Cell anoikis, Metastasis
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Background
Despite the recent progress in hormone and targeted
therapy, breast cancer still remains the second cause of
cancer-related death in women. Most of breast cancer
death is due to metastasis [1]. Therefore, it is important
to determine how the metastasis process is regulated
and to identify potential targets for repressing cancer
metastasis. Breast cancers can be classified into luminal
(A and B), Her2, and basal-like/triple-negative breast
cancer (TNBC) based on the expression status of estro-
gen receptor, progesterone receptor, and Her2/neu [2].
Increased collagen expression and deposition are asso-
ciated with cancer progression and poor prognosis in
breast cancer patients [3]. For instance, type I collagen
has been identified as a prognosis marker and is associ-
ated with cancer recurrence in human breast cancer pa-
tients [4]. Collagen VI knockout mice have reduced
primary tumor formation and growth [5]. Importantly,
the transgenic mice with increased collagen deposition
in mammary tissue have a three-fold increase in tumor
formation. These mice also have three times more lung
metastases [6]. In addition, aligned collagen fibers can
facilitate cell migration and metastasis [7, 8]. These re-
sults suggest that increased collagen deposition can
transform cells into a malignant phenotype and promote
cancer metastasis [9]. Dense breast is a risk factor for
breast cancer [10], and the increased breast density is
due in part to increased deposition of collagen proteins
[11]. In addition, the extracellular matrix (ECM) sur-
rounding a breast tumor is more dense or stiff from in-
creased collagen deposition and crosslink [12]. These
researches indicate that increased collagen expression
and deposition promotes breast cancer development and
progression by enhancing tumor growth and invasion.
The collagen family can be divided into several groups
based on the protein structure and localization [13].
One group of collagen, including collagen XIII, collagen
XXIII, and collagen XXV, is a type II transmembrane
protein [14–17]. Collagen XIII protein is 90 to 100 kDa
and folds in an opposite fashion to the fibrillar collagens.
It has a membrane spanning region near the NC1 do-
main, which results in a large extracellular region with a
short intracellular portion [17]. The function of collagen
XIII at the molecular level has largely remained unclear;
however, it is thought to have a role in cell-cell and
cell-matrix interactions [18]. The extracellular domain
binds integrin [19], and can be cleaved from the cell
resulting in possible paracrine activity in the cellular
microenvironment. When the ectodomain is shed, the
pericellular surrounding is less supportive of cell adhe-
sion, migration and proliferation [20]. The function of
the short intracellular portion after cleavage is unclear
but has been shown to feedback and increase collagen
XIII production [21, 22]. Collagen XIII mRNA has been
shown to be expressed in higher levels in epithelial tu-
mors, such as tumors from the colon, cervix, bladder,
endometrium and ovary [23, 24]. Increased collagen XIII
protein expression is also detected in invasive foci of
bladder cancer [24, 25]. However, the function of colla-
gen XIII in breast cancer progression has not been
determined.
Integrin is one of the cell membrane receptors that
mediate the cell-collagen interaction [26, 27]. Binding of
integrin to collagen induces activation of downstream
signaling, and subsequently modulates cell proliferation,
differentiation, apoptosis and cell migration [28–31]. Ex-
pression of β1 integrin is required for the epithelial in-
tegrity and plays a crucial role in the proliferation of
mammary epithelial cells [32]. Treatment with a β1 in-
tegrin functional blocking antibody can reverse breast
cancer cells back to the normal phenotype in 3D culture
[33]. It has been shown in a mouse mammary tumor
model that disruption of β1 integrin function inhibits
tumor development at the initial stages of mammary
tumor formation [34]. These results suggest that β1 in-
tegrin is a key mediator of collagen-induced cancer de-
velopment and progression.
In this study, we showed that expression of collagen
XIII is higher in breast cancer tissue compared with nor-
mal mammary gland, and that the increased mRNA level
of collagen XIII in cancer tissue is associated with poor
prognosis and cancer metastasis. We also demonstrate
that collagen XIII expression enhanced cancer stemness
and invasive tumor growth through β1 integrin. Import-
antly, silencing collagen XIII in breast cancer cells sig-
nificantly reduced cancer metastasis. These results
identified a novel function of membrane associated col-
lagen in breast cancer progression.
Methods
Cell lines and culture conditions
MDA-MB-231 (ATCC) were maintained in DMEM/F12
with 10% FBS and 1% Pen/Strep. BT549 (ATCC) cells
were maintained in RPMI-1640 with 10% FBS and 1%
Pen/Strep. MCF-10A cells were kind gifts from Michael
W. Kilgore, University of Kentucky, Lexington, KY.
MCF10A cells were cultured as previously described
[35]. Hs-578 T cells (ATCC) were kept as previously de-
scribed [36]. S1 and T4–2 cells are kind gifts from Dr.
Mina J Bissell, and they were cultured as previously de-
scribed [37]. All the cells were tested for mycoplasma
contamination every two months.
Antibodies and reagents
Anti-flag M2 (Sigma, F1804, 1:1000 for WB, 1:500 for IF).
Anti-human β1 integrins,active (Millipore, MAB2079Z,
1:500 for IF). Anti-human Collagen XIII α1 (R&D systems,
AF6346, 1:200 for WB). Anti-smad2/3 (BD Transduction
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Laboratories, 610842, 1:1000 for WB). Anti-p-smad2 (cell
signaling, 130D4, 1:1000 for WB). Anti-tubulin (Cell Sig-
naling, 2148, 1:5000). Anti-Integrin β1 subunit (AIIB2)
(DSHB, 528306, 80 μg/ml for block assay). Anti-rat IgG1
(Santa Cruz Biotechology, sc-3882, 1:1000). Anti-PARP
(Cell Signaling, 9542, 1:1000). Bovine Collagen Solution,
Type I (Advanced BioMatrix, 5005).
Dual-luciferase reporter assay system (Promega, E1960).
Click-It EdU Alexa Fluor 488 Imaging kit (Invitrogen,
C10337). Growth Factor Reduced BD Matrigel™ (BD Biosci-
ences, 354230). Annexin V (Thermo, A13201). Lenti-
CRISPR v2 (Addgene, 52961), pCDH-EF1-MCS-T2A-Puro
(System Biosciences, CD520A-1), p3TP-lux (Addgene,
306281), pGL4.10 (Addgene, 66128).
Plasmid construction
Mouse Collagen XIII (NM_007731.3) were amplified
from constructs pCMV-SPORT6-COL13a1 (Transomic,
BC034164), and cloned into pCDH-EF1-MCS-T2A-Puro





Human Collagen XIII (NM_001130103.1) was amplified
from an expression construct described by Dennis et al. [38],
and cloned into FLAG-tagged pCDH-EF1-MCS-T2A-Puro






Three-dimensional (3D) IrECM on-top culture was per-
formed as previous described [39]. Briefly, Growth Factor
Reduced BD Matrigel™ was plated on the bottom of the
cell culture dish. MDA-MB-231 and MCF10A cells were
seeded on the top of the matrigel layer, and additional
medium containing 10% Matrigel was added on the top.
CRISPR-Cas9 deletion of collagen XIII in MDA-MB-231 and
T4–2 cells
CRISPR-Cas9 plasmid for collagen XIII (NM_001130103.1)
deletion was constructed with gDNA primers: 5’ CACC
GCAGCTCGGCCGTCCGAAAGT 3′ (Forward) and
5’AAACACTTTCGGACGGCCGAGCTGC 3′ (Reverse).
MDA-MB-231 cells were infected with the lentivirus
containing the CRISPR-Cas9 construct, and mono-
clones were selected and verified by genomic DNA se-
quencing and western blot. The collagen XIII-knockout
luciferase-expressing or GFP-expressing MDA-MB-231
cells were pooled together for the mouse experiments.
Western blot and luciferase reporter assay
Protein samples were harvested by using 2% SDS in PBS
with protease inhibitor cocktail and NaF (2.5 mM),
NaVO4 (2 mM). SDS gel electrophoresis, immunoblot
and a LI-COR Odyssey Infrared Imaging System were
employed for detecting the target protein as previously
described [39]. The Image Studio Lite software was used
for quantification.
The Dual-luciferase reporter assay was performed as
previously described [40]. Briefly, MDA-MB-231cells or
MCF10A cells were seeded into a 24-well plate at the
density of 0.1 × 106/well. 24 h later the cells will reach
80% confluence. Then 0.5 μg p3TP-lux and 0.025 μg
renilla plasmids were transfected into the cells using
Fugene HD Transfection Reagent. The cells were starved
before 5 ng/ml TGF-β was added. The relative luciferase
activity was defined as firefly luciferase activity normal-
ized by renilla luciferase activity. The final results were
normalized by the relative luciferase activity of the con-
trol vector pGL4.10.
Transwell invasion and single cell migration assay
The Transwell invasion assay was performed as previously
described [41]. As for the single cell migration assay,
MCF-10A and MDA-MB-231 cells were seeded into a 4
chamber glass bottom dish (Invitro Scientific, D35C4–
20-1-N) at the density of 2000 cell/cm2. About 4 h after
seeding, the single cell migration was monitored by Nikon
BioStation (Nikon, IMQ) every 10 min for 10 h [41]. In
some experiments, the cells were pre-incubated with β1
integrin blocking antibody AIIB2 with the final concentra-
tion of 80 μg/ml for 30 min, and then the Transwell inva-
sion and single cell migration assay were performed in the
presence of the blocking antibody.
Mammosphere/Tumorsphere assay
Cells were seeded in poly-HEMA (12 mg/ml in 95% etha-
nol) pre-coat regular plastic culture dish [42] and cultured
in tumorsphere medium [DMEM/F12 medium supple-
mented with B27 (1:50), EGF (20 ng/ml), bFGF (20 ng/ml),
insulin (5 μg/ml), hydrocortisone (0.5 ng/ml), Gentamicin
(10 μg/ml)] for 5 days without moving or disturbing the
plates. The phase images of mammosphere/tumorsphere
were taken by Nikon eclipse 80i microscope. Mammosphere
or tumorspheres forming efficiency (%) was calculated as
follows: (Number of mammosphere or tumorspheres per
well / number of cells seeded per well) × 100.
Flow cytometry analysis apoptosis
Poly-HEMA (12 mg/ml in 95% ethanol) pre-coated
dishes were used for detachment cell culture [42].
MCF-10A and MDA-MB-231 cells were cultured in
regular media with 0.5% methyl cellulose in suspension
at a density of 30,000 cells per cm2 [42]. Cells were
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cultured in suspended condition for 24 h. And then were
collected for annexin V analysis as manufacturer’s
instructions.
Immunofluorescence staining
For immunofluorescence staining, cells were cultured in
a chamber slide (Nalge Nunc International, 154526).
The cells were fixed with Methanol/Acetone (1:1) or for-
malin and permeabilized with 0.5% Triton X-100. The
slides were blocked by 10% goat serum at room
temperature for 60 min, and incubated with the primary
antibodies (anti-flag/anti-active-β1 integrin/anti-caspase
3) at 4 °C overnight. The slides were incubated with sec-
ondary antibodies at room temperature for 60 min. Im-
ages were taken with Nikon Eclipse 80i fluorescence
microscope and Nikon eclipse Ti2 confocal microscope.
Cell proliferation assay
Cell proliferation was performed per the instructions of
the Click-It EdU Alexa Fluor 488 Imaging kit and
assessed by quantification of the proportion of cells with
EdU-positive staining. The number of nuclei positive for
EdU was counted and divided by the total number of
nuclei (DAPI).
Xenograft experiment and in vivo colonization experiments
For the xenograft experiment, 6-week old female SCID
mice were randomly grouped and injected with 2 × 106 con-
trol or collagen XIII-silenced MDA-MB-231-luc-D3H2LN
cells at 4th mammary fat pad. Tumors were measured with
a caliper every other day. Tumor volume (mm3) was esti-
mated using the formula [volume = π × (width)2 × (length) /
6]. Twenty five days after tumor cell implantation, the pri-
mary tumors are removed by surgery. To detect lung me-
tastasis, bioluminescent images were taken at 3 weeks after
primary tumor removal with in vivo imaging system (IVIS).
For lung colonization experiment, 6-week old female
SCID mice were randomly grouped and injected with
0.5 × 106 (in 200 μl PBS) control or collagen XIII-silenced
MDA-MB-231-luc-D3H2LN cells via tail vein. To detect
lung metastasis, bioluminescent images were taken once a
week begining 4 weeks after the injection of cancer cells
with IVIS. At the experimental endpoint, lung tissues were
harvested and fixed with 4% PFA for paraffin-embedded
section. H&E staining was performed in lung tissue sec-
tions, and images were taken by a Nikon microscope. Me-
tastasized tumors in the lung were quantified by counting
three sections per lung sample. For the intracardiac inocu-
lation experiment, 6-week old female nude mice were ran-
domly grouped. 0.2 × 106 (in 100 μl PBS) control, collagen
XIII-silenced MDA-MB-231-luc-D3H2LN cells or colla-
gen XIII-silenced MDA-MB-231-GFP cells were injected
into left cardiac ventricle. Bioluminescent images were
taken once a week to detect lung and bone metastasis.
Illumatool was used to detect GFP labeled cells
metastasis.
Statistical analysis
To address the clinical relevance of increased collagen
XIII expression, we assessed the association between
mRNA levels of Col13A1 and recurrence or distant re-
currence free survival using the published microarray
dataset generated from 3554 human breast cancer tissue
samples [43] (2014 version). Patients were equally
grouped into low and high Col13A1 expression based on
the mRNA levels. Significant differences in recurrence
or distant recurrence survival time were assessed with
the Cox proportional hazard (log-rank) test.
All experiments were conducted by three independent
experiments. Data were reported as mean ± s.e.m.. Stu-
dent’s t-test (two groups) or one-way ANOVA (three or
more groups) were used to determine the significant dif-
ferences between means. Statistical analysis was per-
formed with Graph Pad Prism 5 and IBM SPSS Statistics
22. p < 0.05 represents statistical significance and p < 0.01
represents sufficiently statistical significance. All reported
p values were from two-sided tests.
Results
Collagen XIII expression is increased during breast cancer
development
To determine whether collagen XIII expression is in-
duced during breast cancer development, we analyzed
collagen XIII protein levels in a panel of non-malignant
and malignant mammary epithelial cells. Triple negative
breast cancer cell line MDA-MB-231, Hs578T, BT549,
and T4–2 expressed higher levels of collagen XIII pro-
tein than luminal type breast cancer cell lines and
non-malignant mammary epithelial cell lines (Fig. 1a).
By analyzing TCGA and Finak datasets (www.oncomi
ne.com), we found that collagen XIII mRNA levels were
significantly increased in human breast cancer tissue
compared to normal mammary gland tissue (Fig. 1b, c).
Collagen XIII expression in ER negative breast cancer
was much higher than the expression in ER positive
breast cancer (Fig. 1d). Consistence with cancer cell line
data, we also found that triple negative breast cancer tis-
sue had higher level of collagen XIII expression com-
pared with other subtypes (Fig. 1e).
Next, we asked whether collagen XIII expression is as-
sociated with clinical outcome in human breast cancer
patients. Breast cancer patients were divided into two
groups based on collagen XIII mRNA levels (low and
high). Kaplan-Meier log rank analysis showed that pa-
tients whose tumors had high collagen XIII expression
levels had a significantly shorter overall survival period
(Fig. 1f ). Moreover, the association of collagen XIII ex-
pression with poor clinical outcome is stronger in ER
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negative breast cancer (Fig. 1g). Although collagen XIII
mRNA levels are lower in ER positive breast cancer
compared to ER negative cancer, increased collagen XIII
expression in ER positive breast cancer is still associated
with poor clinical outcome (Additional file 1: Figure S1).
These results indicate that breast cancer development
and progression are accompanied by increased expres-
sion of collagen XIII.
Collagen XIII promotes invasive 3D malignant phenotypes
in MDA-MB 231 cells.
Increased expression of collagen XIII has been detected in
several types of cancer [24, 25]. However, function of colla-
gen XIII in cancer progression is not clear. Since collagen
XIII protein is highly expressed in MDA-MB-231 cells but
non-detectable in MCF-10A cells, these cell lines were used
for loss- and gain-of function experiments, respectively, to
define roles of collagen XIII in breast cancer progression.
Collagen XIII expression was silenced in MDA-MB-231
cell line using CRISPR technology (Fig. 2a, b and
Additional file 2: Figure S2). 3D culture models have been
widely used to examine the malignant mammary tissue
morphogenesis [44, 45]. Invasive branching structure in 3D
culture is associated with cancer invasion and aggressive
cancer phenotypes [36, 41]. We showed that silencing col-
lagen XIII in MDA-MB-231 significantly reduced the num-
ber of invasive branches and inhibited invasive growth in
3D culture (Fig. 2c). For the gain-of function experiments,
MCF10A cells were infected with lentivirus containing
the collagen XIII expression construct. The majority of
exogenous collagen XIII was detected on cell surface
(Fig. 2d, 2e, and Additional file 3: Figure S3a). We
found that collagen XIII expression increased 3D col-
ony size in MCF10A cells (Fig. 2f ). The ratio of EdU
positive cells was significantly higher in the collagen
XIII expression group compared with the control group
(Fig. 2g, Additional file 3: Figure S3b). A reduction of
activated caspase 3 staining was also detected in colla-
gen XIII-expressing cells (Additional file 3: Figure S3c).
Invasive growth of breast cancer in 3D culture depends
on cancer cell invasion and migration [46, 47]. Thus, we
asked whether collagen XIII regulates invasion and migra-
tion of mammary epithelial cells. Silencing collagen XIII
significantly reduced invasion of MDA-MB-231 cells in
Transwell experiments (Fig. 3a). Using single cell tracking
analysis, we showed that knockout of collagen XIII
Fig. 1 Collagen XIII expression is increased during breast cancer development. a Western blot analysis of Collagen XIII (Col13) in the malignant and
non-malignant mammary epithelial cell lines in vitro. Red stands for triple negative breast cancer cell lines, blue stands for luminal type breast cancer
cell lines, black stands for non-malignant mammary epithelial cell lines. b Col13 mRNA expression in human breast cancer and normal mammary
tissues in the TCGA dataset. n = 593 ** p < 0.01. c Col13 mRNA expression in human breast cancer and normal mammary tissues in the Finak dataset.
n = 59 ** p < 0.01. d Col13 mRNA levels in ER negative (n = 91) and ER positive (n = 270) subgroups of breast cancer patients; ** p < 0.01. e Col13
mRNA expression in triple negative breast cancer tissues (n = 48) and other subtypes (n = 473); results are presented as the mean ± s.e.m.; ** p < 0.01.
f Kaplan-Meier analysis of recurrence free survival of breast cancer patients grouped into high and low expression levels of Col13. The patients were
equally divided into two groups based on the mRNA levels of Col13 in breast cancer tissues, n = 3554; *** p < 0.001. g Kaplan-Meier analysis of
recurrence free survival of estrogen receptor negative patients grouped into high and low expression levels of Col13. n = 671; *** p < 0.001
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Fig. 2 Collagen XIII promotes invasive 3D malignant phenotypes. a Schematic representation of human Col13A1 gene. Blue block represents
exons. The area of the exon corresponding to the target region for CRISPR/Cas9 based gene editing is highlighted in red. The genomic
sequencing results of the wildtype and mutant clones are presented in the box. A deletion was detected in Col13 knockout clone (Col13−/− (28)).
b Western blot was performed to confirm Col13 knockout in Col13−/− (25) and Col13−/− (28) clones compared with control MDA-MB-231 cells.
c Representative phase microscopy images of phenotype of MDA-MB-231 control and Col13−/− MDA-MB-231 cells under 3D matrix culture (left).
Bar graph quantifying the invasive branches in MDA-MB-231 control and two Col13−/− clones (right). Results are presented as the mean ± s.e.m.;
n = 100; *** p < 0.001. Scale bar: 50 μm. d Western blot analysis of flag-tagged Col13 and tubulin in cell lysate of control and Col13-expressing
MCF-10A cells. e Fluorescence and phase images of control and col13-expression MCF-10A cells in 3D culture. Scale bars: 20 μm. f Line chart
showing quantification of the diameter of control and Col13-expression MCF-10A cells at different time points in 3D culture. Data are presented
as the mean ± s.e.m.; n = 60; * p < 0.05, *** p < 0.001; n.s., no significance. g Quantitative analysis of the cell proliferation of control and
Col13-expression MCF-10A by EdU staining. Line chart representing the ratio of EdU positive to total cells. (day4, n = 20; day6, n = 20; day8, n = 20;
day10, n = 20); *** p < 0.001; n.s., no significance
Fig. 3 Collagen XIII enhances cancer cell migration and invasion. a Phase images (left) and quantification data (right) showing invasion of control
and Col13−/− MDA-MB-231 cells in the Transwell analysis. Data are presented as the mean ± s.e.m.; n = 3; ** p < 0.01. Scale bar: 100 μm. b
Quantification of velocity and path length of control and Col13−/− MDA-MB-231 cells in the single cell migration analysis (Control, n = 22; clone25,
n = 30; clone 28, n = 65); * p < 0.05. c Phase images (left) and quantification data (right) showing the invasion of control and Col13-expressing
MCF-10A cells in Transwell experiments; n = 3; * p < 0.05. Scale bar: 100 μm. d Quantification of velocity and path length of control and Col13-
expressing MCF-10A cells in the single cell migration analysis; n = 25; *** p < 0.001
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reduced the velocity and the distance of cell migration in
MDA-MB-231 cells (Fig. 3b). In contrast, MCF-10A cells
with collagen XIII overexpression were more invasive than
control cells (Fig. 3c). Collagen XIII expression also sig-
nificantly increased the cell migration velocity and dis-
tance in MCF-10A (Fig. 3d, and Additional file 4: Figure
S4a, b). These results indicate that increased expression of
collagen XIII in MDA-MB 231 cells promotes malignant
phenotypes in 3D culture by enhancing cancer cell migra-
tion and invasion. Collagen XIII is expressed at the inter-
mediate level in malignant T4–2 cells (Fig.1a), and we
performed both loss- and gain-of-function experiments
using this cell line. Silencing collagen XIII reduced T4–2
invasion, while overexpression of collagen XIII did not sig-
nificantly enhance cell invasion in the Transwell experi-
ments (Additional file 5: Figure S5). Therefore, the
moderate expression of collagen XIII may be sufficient
to promote cancer invasion. To determine whether col-
lagen XIII regulates cell invasion in a cell-autonomous
fashion, we performed co-culture experiments by mix-
ing GFP-labeled collagen XIII-silenced MDA-MB-231
cells with non-labeled wild type MDA-MB-231 cells.
We found that wild type MDA-MB-231 cells could not
rescue cell invasion in the collagen XIII-silenced cells
(Additional file 6: Figure S6). These results suggest that
collagen XIII promotes cancer cell invasion through the
receptor on the same cells.
Collagen XIII expression enhances cancer cell stemness.
Tumor-initiating cells are the driver of cancer relapses and
metastasis [48, 49]. The tumorsphere assay has been used to
enrich tumor-initiating cells and to study their colony for-
mation activity [50, 51]. By analyzing the published micro-
array dataset [52], we found that collagen XIII expression
was upregulated in tumor spheroids compared to the corre-
sponding primary tumors (Fig. 4a). To determine whether
collagen XIII contributes to tumorsphere formation, we cul-
tured control, collagen XIII-silenced MDA-MB-231 and
T4–2 cells in non-adhesive plates. We found that silencing
collagen XIII significantly reduced tumorsphere formation
in both MDA-MB-231 and T4–2 cells (Fig. 4b and
Additional file 7: Figure S7a). In contrast, expression of col-
lagen XIII enhanced mammosphere formation in MCF10A
cells (Fig. 4c). Interestingly, overexpression of collagen XIII
in T4–2 had little effect on tumorsphere formation, suggest-
ing that the moderate expression of collagen XIII is
Fig. 4 Collagen XIII expression enhances cancer cell stemness. a Quantification of mRNA levels of Col13 in primary tumors (n = 11) and
tumorsphere (n = 15). Data are presented as the mean ± s.e.m.; * p < 0.05. b Phase images and quantification data showed tumorshpere formation
in control and Col13−/− MDA-MB-231 cells; n = 5; *** p < 0.001. Scale bar: 200 μm. c Phase images and quantification data showed
mammosphere formation in control and Col13-expressing MCF-10A cells; n = 6; *** p < 0.001. Scale bar: 200 μm. d. Cell detachment induced
apoptosis was quantified in control and Col13-expressing cells. Cells were cultured with 0.5% methyl cellulose in suspension for 24 h to induce
anoikis before the analysis. Cell surface phosphatidylserine was analyzed by annexin-V and followed by flow cytometry analysis. Early apoptosis
was quantified with bar graph; n = 3; ** p < 0.01. e Western blot analyzing PARP-cleavage in control and Col13-expressing MCF-10A cells. Cells
were treated as described in d before the analysis. f Cell detachment induced apoptosis was quantified in control and Col13−/− MDA-MB-231 as
described in d. Data are presented as the mean ± s.e.m.; n = 3; *** p < 0.001
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sufficient to enhance cancer cell stemness (Additional file 7:
Figure S7b). Next, we performed another tumorsphere for-
mation experiments by mixing GFP-labeled collagen
XIII-silenced MDA-MB-231 cells with non-labeled wild type
MDA-MB-231 cells. Wild type MDA-MB-231 cells did not
increase the tumorsphere formation efficiency in
GFP-labeled collagen XIII-silenced cells (Additional file 8:
Figure S8). These results suggest that collagen XIII enhances
cancer cell stemness in a cell-autonomous manner.
Tumor initiating cells are more resistant to
detachment-induced anoikis, which is crucial for the
cancer cell survival during cancer metastasis [53]. To de-
termine whether collagen XIII promotes anoikis resist-
ance, control, collagen XIII-silenced MDA-MB-231, and
collagen-expressing MCF10A cells were cultured in me-
thyl cellulose. Cell anoikis was assessed by analyzing
PARP cleavage and cell surface-expressed phosphatidyl-
serine with FITC-labeled annexin-V. We found that col-
lagen XIII expression reduced detachment-induced cell
surface-expressed phosphatidylserine and PARP cleavage
in MCF-10A cells (Fig. 4d, e), while silencing collagen
XIII increased annexin-V staining in MDA-MB-231 cells
(Fig. 4f ). These results suggest that collagen XIII pro-
motes breast cancer progression by enhancing cancer
cell stemness and its associated anoikis resistance.
Collagen XIII enhances tumorsphere formation and TGF-β
signaling through β1 integrin
To understand how collagen XIII regulates cancer pro-
gression, we determined whether collagen XIII induces
β1 integrin activation. Monoclonal antibody HUTS-4 is
specific against active human β1 integrin [54]. Activated
β1 integrin was analyzed by immune fluorescence stain-
ing with HUTS-4 in control, collagen XIII-silenced or
collagen XIII-expressing cells. Quantified data showed
that silencing collagen XIII reduced the activated β1 in-
tegrin foci in MDA-MB-231 cells (Fig. 5a). In contrast,
expression of collagen XIII induced β1 integrin
Fig. 5 Collagen XIII enhances cancer cell invasion and stemness through β1 integrin. a Immune fluorescence imaging analysis of β1 integrin
activation in control and Col13−/− MDA-MB-231 cells (left). Bar graph quantifying the foci number of activated β1 integrin staining on cell
membrane in control and Col13−/− MDA-MB-231 cells (right). Data are represented as the mean ± s.e.m.; n = 10 (fields); ** p < 0.01, *** p < 0.001.
Scale bar: 5 μm. b Immune fluorescence imaging analyzed β1 integrin activation in control and Col13-expressing MCF-10A cells (left). Bar graph
quantifying the foci number of activated β1 integrin staining on cell membrane in control and Col13-expressing MCF-10A cells (right); n = 10
(fields); ** p < 0.01. Scale bar: 5 μm. c The velocity (left) and path length (right) of single cell migration were quantified in Col13-expressing
MCF-10A cells in the presence of β1 integrin functional blocking antibody AIIB2 or control IgG; n = 27; *** p < 0.001; n.s., no significance. d Bar
graph quantifying invasion of Col13-expressing MCF-10A cells in the presence of AIIB2 or IgG; n = 3; ** p < 0.01. e Bar graph quantifying the
mammosphere forming efficiency of Col13-expressing MCF-10A cells in the presence of AIIB2 or IgG; n = 3; * p < 0.05. f Western blot data
showing that AIIB2 treatment enhanced PARP-cleavage in Col13-expressing MCF-10A cells
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activation in MCF-10A cells (Fig. 5b). AIIB2 is an antibody
that blocks β1 integrin activity [33]. To determine whether
β1 integrin activation is crucial for collagen XIII-induced
cell function, the collagen XIII-expressing MCF10A cells
were treated with the control IgG or AIIB2 antibody in
the single cell migration, invasion, and mammosphere for-
mation experiments. We showed that the AIIB2 treatment
blocked collagen XIII-induced cell migration (Fig. 5c),
invasion (Fig. 5d), and mammosphere formation in
MCF10A cells (Fig. 5e), while IgG treatment had little ef-
fect. In addition, inhibition of β1 integrin activation en-
hanced PARP cleavage in collagen-expressing cell (Fig. 5f).
These results indicate that collagen XIII enhances cell in-
vasion and mammosphere formation at least partially
through the β1 integrin pathway.
Aberrant activation of the TGF-β pathway promotes
cancer progression by enhancing cancer cell stemness and
invasion [55–57]. It has been shown that β1 integrin con-
tributes to the activation of the TGF-β pathway [58, 59].
We asked whether collagen XIII enhances the TGF-β sig-
naling through β1 integrin. Control and collagen XIII
knock-out MDA-MB-231 clones were treated with
TGF-β1. The cell lysates at various time points were
analyzed by western blot to determine the ratio of phos-
phorylated SMAD2/3 compared to total SMAD. The
TGF-β-induced SMAD2/3 phosphorylation was decreased
in the collagen XIII knockout clones compared to control
MDA-MB-231 cells (Fig. 6a). Consistent with western blot
data, the TGF-β-induced TPA response elements (TREs)--
driven luciferase activities were significantly reduced in
collagen XIII-silenced cells (Fig. 6b). These experiments
were repeated in the MCF-10A cells. Results showed that
the TGF-β-induced SMAD2/3 phosphorylation and re-
porter activities were enhanced by exogenous collagen
XIII expression (Fig. 6c, d). Importantly, AIIB2 treatment
significantly reduced the collagen XIII-enhanced SMAD2/
3 phosphorylation (Fig. 6e). Therefore, collagen XIII ex-
pression may enhance the TGF-β signaling through β1 in-
tegrin which subsequently promotes cancer progression.
Silencing collagen XIII inhibits breast cancer metastasis in
mice
We showed that expression of collagen XIII was associ-
ated with short distant recurrence free survival in
Fig. 6 Collagen XIII enhances activation of the TGF-β pathway. a Western blot analyzed TGF-β-induced Smad phosphorylation in control and
Col13−/− MDA-MB-231 cells. b Bar graph quantifying TGF-β-induced TPA response elements (TREs)-driven luciferase activity in control and Col13−/
− MDA-MB-231; n = 3; ** p < 0.01. c Western blot analyzed TGF-β-induced Smad phosphorylation in control and Col13-expressing MCF-10A cells.
d Bar graph showing TGF-β-induced TRE-driven luciferase activity in control and Col13-expressing MCF-10A cells; n = 4, *** p < 0.001. e AIIB2
treatment reduced the level of TGF-β-induced Smad2/3 phosphorylation in Col13-expressing MCF-10A cells. Western bolt images (left) and
quantification (right); n = 3; *** p <0.001; n.s., no significance
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patients with ER negative (Fig. 7a) and ER positive breast
cancer (Additional file 9: Figure S9), suggesting that col-
lagen XIII contributes to cancer metastasis. To deter-
mine whether collagen XIII expression promotes cancer
cell colonization at distant organs, we silenced collagen
XIII expression in MDA-MB-231-luc-D3H2LN cells and
pooled multiple clones together (Additional file 10:
Figure S10). Control and collagen XIII-silenced cells
were injected into the tail veins of SCID mice. Lung
colonization of the cancer cells was monitored by IVIS
imaging. We showed that the mice injected with control
cells developed lung metastasis within 5 weeks, while si-
lencing collagen XIII significantly reduced the lung me-
tastasis (Fig. 7b). Haemotoxylin and Eosin (H&E)
staining further confirmed that silencing collagen XIII
inhibited the lung colonization of cancer cells in SCID
mice (Fig. 7c). Intracardiac inoculation of MDA-MB-231
cells has been used as a model to investigate breast can-
cer bone metastasis. Using this model, we also found
that silencing collagen XIII reduced colonization of
MDA-MB-231-luc-D3H2LN cells in nude mice (Fig. 7d).
We further analyzed cancer cell colonization in bone
using the GFP-labeled MDA-MB-231 cells. Interestingly,
bone metastasis was detected in all four mice in the
collagen-silenced group, while only three mice had bone
metastasis in the control group (Additional file 11:
Figure S11). Thus, function of collagen XIII in breast
cancer bone metastasis remains for further clarification.
Next we defined roles of collagen XIII in primary
tumor growth and cancer metastasis using the
MDA-MB-231-luc-D3H2LN orthotopic mammary
tumor model [60]. The orthotopic mammary tumor
model is a physiologically relevant model to study
cancer metastasis. It reproduces the entire metastatic
process, including tumor cell dissemination from the
mammary fat pad, followed by colonization and out-
growth at distant organs. The same amount of control
and collagen XIII-silenced cancer cells were injected
into the mammary fat pads of 6-week-old female SCID
mice, and tumor growth was monitored twice per
week. Then the primary tumors were removed, and
mice were maintained for another month before
Fig. 7 Collagen XIII promotes cancer metastasis in xenograft models. a Kaplan-Meier analysis of distant recurrence free survival of ER negative
breast cancer patients; the patients were equally divided into high and low expression levels of collagen XIII. n = 170. **p <0.01. b IVIS images
(left) and quantification (right) of tail vain lung metastasis in control and Col13−/− 231-luc-D3H2LN cells injected mice. Data are presented as the
mean ± s.e.m.; n = 5, * p < 0.05. c H&E staining (left) and quantification (right) of lung metastasis nodules in control and Col13−/− 231-luc-D3H2LN
cells injected mice; n = 4; * p < 0.05. d IVIS images (left) and quantification (right) showed over all metastasis of control and Col13−/− 231-luc-
D3H2LN cells via intracardiac inoculation. Data are presented as the mean ± s.e.m.; n = 3, p = 0.09. e Tumor growth curve of control and Col13−/−
231-luc-D3H2LN implanted mice. On day 23 and 25 showed statistical significance; n = 6; * p < 0.05. f H&E staining (left) and quantification (right)
of lung metastasis nodules in mice 3 weeks after primary tumor removal; n = 5; p = 0.164
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analyzing the metastases in the lung. We found that
silencing collagen XIII slightly reduced tumor growth
(Fig. 7e). We also observed a reduction of lung metas-
tases in collagen XIII-silenced group (Fig. 7f ). There-
fore, increased collagen XIII expression may promote
cancer colonization and metastasis by enhancing can-
cer cell invasion and stemness.
Discussion
Roles of interstitial collagen and BM collagen in
mammary tumor development have been determined
[61–63]. However, function of membrane-associated
collagens in breast cancer is not well studied. We
identified increased collagen XIII expression in breast
cancer tissue, especially in triple negative breast can-
cers. Using the orthotopic mammary tumor model
and lung colonization assay, we showed for the first
time that collagen XIII expression is required for
breast cancer cell metastasis. These results identified
a novel function of membrane associated collagen in
cancer progression.
Stromal cells, such as cancer-associated fibroblasts,
are considered the major source of ECM protein in
cancer tissue. It has been shown that collagen XIII is
highly expressed in fibroblasts and localizes in the focal
adhesion [24]. Interestingly, we found that collagen XIII
is expressed in TNBC cell lines and tissues. The
metastatic MDA-MB-231 cell line contains the highest
level of collagen XIII compared to non-metastatic or
non-malignant cell lines. A recent study shows that col-
lagen XIII is expressed in the invasive bladder cancer
cell line and the infiltrative bladder cancer tissue. Colla-
gen XIII enhances cancer cell invasion in these cell
lines [25]. We further show that the increased expres-
sion of collagen XIII promotes cancer cell migration
and invasion through β1 integrin. Collagen I, collagen
IV, laminin, and fibronectin are also produced by can-
cer cells and deposited in cancer tissue [36, 64–66].
These results indicate that cancer cells produce a sig-
nificant amount of ECM proteins. Importantly, we
demonstrate that collagen XIII is crucial for cancer cell
stemness and metastasis, which provide additional in-
sights about the cancer cell produced ECM.
Results from lung colonization experiments suggest
that collagen XIII expression is crucial for cancer cell
survival in circulation and colonization at distant or-
gans. It has been shown that tumor initiating cells are
the driver of cancer metastasis and initiate the
colonization at distal sites [67, 68]. Silencing collagen
XIII reduced tumorsphere formation in breast cancer
cells, suggesting that the collagen XIII expression en-
hances cancer cell stemness. Cancer cells also need to
acquire anoikis resistance to survive in circulation
during cancer metastasis. We found that collagen XIII
induces anoikis resistance in mammary epithelial cells.
These results suggest that collagen XIII derived from
cancer cells promotes cancer metastasis by enhancing
cancer cell stemness and by inducing anoikis
resistance.
Collagen XIII expression is detected in the inva-
sion front of bladder cancer [24, 25]. Consistent
with these results we show that collagen XIII is re-
quired for the invasive growth of MDA-MB-231 cells
in 3D culture. Therefore, membrane protein collagen
XIII may promote cancer cell metastasis at multiple
stages, including dissemination from the primary
tumor and colonization at the distant organs. Inter-
estingly, collagen XIII is also involved in the inflam-
matory process and regulation of the immune
system. It has been identified as a favorable prognos-
tic factor in B-cell lymphoma [69]. In addition, mice
expressing a mutant collagen XIII develop clonal
mature B cell lineage lymphomas [70]. These results
suggest that function of collagen XIII in the devel-
opment of solid tumors and lymphoma may be
different.
We found that collagen XIII expression induced
the activation of β1 integrin. Inhibition of β1 integ-
rin activation blocks collagen XIII-induced tumor-
sphere formation and TGF-β signaling, suggesting
that β1 integrin is a crucial downstream target of
collagen XIII in promoting cancer progression. It
has been shown that integrin α1β1 mediates CHO
cell spreading on collagen XIII [19]. The solid phase
assay confirms the binding of europium-labeled αI
domains to the collagen XIII. Our co-culture experi-
ments suggest that collagen XIII binds to the integ-
rin on the same cell and enhance cell invasion and
tumorsphere formation in the cell-autonomous man-
ner. Discoidin domain receptors (DDRs) are a family
membrane proteins that bind to collagen separated
from the integrin-β1 pathway [71, 72]. DDRs are
tyrosine kinase receptors that are activated when
bound to collagen, subsequently regulating cell pro-
liferation, differentiation, survival, and migration
[73]. Therefore, it is important to investigate if colla-
gen XIII also regulates DDR activation in the future.
Conclusions
In summary, this study identified a novel function of
collagen XIII in breast cancer metastasis. We dem-
onstrate that collagen XIII enhances breast cancer
invasive growth and anoikis resistance through β1
integrin. These findings provide insights in the roles
of membrane associated collagen in cancer progres-
sion, and suggest that targeting collagen XIII is a
potential strategy for suppressing breast cancer
progression.
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Additional file 1: Figure S1. Kaplan-Meier analysis of recurrence free
survival in ER positive breast cancer patients; the patients were equally
divided into two groups based on the mRNA level of Col13 in breast
cancer tissue. n = 1802. **p < 0.01. (PDF 2061 kb)
Additional file 2: Figure S2. Genomic DNA sequencing results of wild
type and Col13 knockout MDA-MB-231 clone 28. There is a T deleted in
the Col13 knockout MDA-MB-231 cells. (PDF 3096 kb)
Additional file 3: Figure S3. Immunofluorescence staining analyzes
collagen XIII expression, EdU labeling, and caspase 3 activation. a 2D
culture fluorescent microscopy images of MCF-10A control and Col13
overexpression cells. Flag (green), dapi (blue) and merged images. Scale
bar: 20 μm. b EdU staining fluorescent microscopy images of MCF-10A
control and Col13 overexpression cells. Representative image was on
day6 of 3D culture. EdU (green), dapi (blue) and merged images. Scale
bar: 20 μm. c The images (left) stand for caspase3 3D fluorescent staining
and the bar graph (right) shows the ratio of caspase3 positive to total
cells. Caspase3 (green), dapi (blue). Scale bar: 20 μm. Data are presented
as the mean ± s.e.m. (n = 20); p = 0.098. (PDF 4348 kb)
Additional file 4: Figure S4. The path of single cell migration in control
(left) and Col13-expressing MCF-10A cells (right); n = 13. (PDF 1546 kb)
Additional file 5: Figure S5. Transwell analysis of T4–2 cell invasion.
a Quantification data showing invasion of control and Col13−/− T4–2 cells.
Data are presented as the mean ± s.e.m.; n = 3; * p < 0.05. b Quantification
data showing invasion of control and Col13-expressing T4–2 cells. Data are
presented as the mean ± s.e.m.; n = 3; n.s., no significance. (PDF 1423 kb)
Additional file 6: Figure S6. Co-culture invasion analysis in Transwell.
Images (upper) and quantification data (lower) showing the invasion of
GFP-labeled MDA-MB-231-vector control cells mixed with wild type MDA-
MB-231 cells (1:1), GFP-labeled Col13−/− MDA-MB-231 cells alone, and
GFP-labeled Col13−/− MDA-MB-231 cells mixed with wild type MDA-MB-
231-Control cells (1:1). Each group had same amount of cells plated in
the upper chamber; total cell number plated in the upper chamber is
0.1 M. The invaded GFP-labeled cell numbers were counted, and the
number of GFP-labeled Col13−/−MDA-MB-231 alone group was divided
by 2. Data are presented as the mean ± s.e.m. n = 3; ** p < 0.01. n.s., no
significance. Scale bar: 50 μm. (PDF 4617 kb)
Additional file 7: Figure S7. Tumorsphere forming efficiency in T4–2 cells.
a Phase images (left) and quantification data (right) showed tumorshpere
formation efficiency in control and Col13−/−T4–2 cells. Data are presented as
the mean ± s.e.m. n = 3; * p < 0.05. Scale bar: 100 μm. b Phase images (left)
and quantification data (right) showed tumorshpere formation efficiency in
control and Col13-expressing T4–2 cells. Data are presented as the mean ±
s.e.m. n= 3; n.s., no significance. Scale bar: 100 μm. (PDF 5721 kb)
Additional file 8: Figure S8. Co-culture tumorsphere forming efficiency
analysis. Quantification data showing tumorsphere forming efficiency of
GFP-labeled MDA-MB-231 vector control cells mixed with wild type MDA-
MB-231 cells (1:1), GFP-labeled Col13−/− MDA-MB-231 cells alone, and
GFP-labeled Col13−/− MDA-MB-231 mixed with wild type MDA-MB-231
cells (1:1). Each group had the same amount of cells plated on poly-
HEMA coated dishes, and GFP-labeled tumorsphere was counted, and
the tumorsphere number of GFP-labeled Col13−/− MDA-MB-231alone
group was divided by 2. Data are presented as the mean ± s.e.m. n = 3; *
p < 0.05, ** p < 0.01. n.s., no significance. (PDF 1452 kb)
Additional file 9: Figure S9. Kaplan-Meier analysis of distant recurrence
free survival in ER positive breast cancer patients; the patients were
equally divided into two groups based on the mRNA level of collagen
XIII. n = 577. ***p < 0.001. (PDF 2351 kb)
Additional file 10: Figure S10. Western blot confirming Col13
knockout in 231-luc-D3H2LN cells. (PDF 1372 kb)
Additional file 11: Figure S11. Bright field and fluorescence images
showing bone metastasis of GFP-labeled MDA-MB-231 cells in nude mice.
Left two images showed bone metastasis of the control MAD-MB-231
cells on the hind leg after intracardiac inoculation. Right two images
showed bone metastasis of Col13−/− MAD-MB-231 cells on the fore leg
after intracardiac inoculation. n = 4. (PDF 7411 kb)
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